...
首页> 外文期刊>Chemical and Pharmaceutical Bulletin >Self-microemulsifying Drug Delivery System Improved Oral Bioavailability of 20(S)-Protopanaxadiol: From Preparation to Evaluation
【24h】

Self-microemulsifying Drug Delivery System Improved Oral Bioavailability of 20(S)-Protopanaxadiol: From Preparation to Evaluation

机译:自微乳化药物递送系统提高了20(S)-普萘他那二醇的口服生物利用度:从制备到评估

获取原文
获取原文并翻译 | 示例
           

摘要

20(S)-Protopanaxadiol (20(S)-PPD) is one type of sapogenin of protopanaxadiols and has a variety of pharmacological activities. In order to improve the dissolution of 20(S)-PPD as well as its oral bioavailability, a self-microemulsifying drug delivery system (SMEDDS) was utilized for 20(S)-PPD preparation. Following the preparation of the 20(S)-PPD SMEDDS, its dissolution, stability, and intestinal absorption in rats were studied, and the pharmacokinetics and optimal dosage after oral administration were evaluated. The dissolution tendency of the SMEDDS in phosphate buffered saline (PBS), 0.1 M HCl and distilled water was consistent. SMEDDS was stable under a condition of high temperature (40 degrees C), high humidity or with strong light irradiation, or within 6h in artificial digestive tracts. 20(S)-PPD SMEDDS was well-absorbed in all intestinal segments in rats. When the drug concentration was higher than 200 mu g/mL or the perfusion flow was faster than 0.5 mL/min, passive diffusion of drug in the duodenum reached a saturated level. In addition, P-glycoprotein inhibitor did not affect the intestinal absorption of 20(S)-PPD SMEDDS. Pharmacokinetic study showed that T-max in male rats was shortened significantly, while C-max and area under the curve (AUC((0-t))) were remarkably increased. The relative oral bioavailability of 20(S)-PPD SMEDDS was increased approximately three fold compared with the 20(S)-PPD carboxy methyl cellulose (CMC). 20(S)-PPD SMEDDS (100 mg/mL) was administered by gastric infusion to both mice and rats for 14d. SMEDDS improved the oral bioavailability of 20(S)-PPD and reduced the necessary drug dosage. 20(S)-PPD SMEDDS could become a promising clinical alternative as an anti-tumor or antidepressant drug.
机译:20(S)-普萘普生二醇(20(S)-PPD)是一种原皂甙元的皂甙元,具有多种药理活性。为了提高20(S)-PPD的溶解度和口服生物利用度,将自微乳化药物递送系统(SMEDDS)用于20(S)-PPD的制备。制备20(S)-PPD SMEDDS后,研究了其在大鼠中的溶解,稳定性和肠道吸收,并评估了口服后的药代动力学和最佳剂量。 SMEDDS在磷酸盐缓冲盐水(PBS),0.1 M HCl和蒸馏水中的溶解趋势一致。 SMEDDS在高温(40摄氏度),高湿度或强光照射下,或在人工消化道中的6h内是稳定的。在大鼠的所有肠段中都充分吸收了20(S)-PPD SMEDDS。当药物浓度高于200μg / mL或灌注流量高于0.5 mL / min时,药物在十二指肠中的被动扩散达到饱和水平。此外,P-糖蛋白抑制剂不影响20(S)-PPD SMEDDS的肠道吸收。药代动力学研究表明,雄性大鼠的T-max明显缩短,而C-max和曲线下面积(AUC((0-t)))则显着增加。与20(S)-PPD羧甲基纤维素(CMC)相比,20(S)-PPD SMEDDS的相对口服生物利用度提高了约三倍。通过胃输注向小鼠和大鼠给药20(S)-PPD SMEDDS(100 mg / mL),持续14天。 SMEDDS改善了20(S)-PPD的口服生物利用度,并减少了必要的药物剂量。 20(S)-PPD SMEDDS可以作为抗肿瘤或抗抑郁药成为有希望的临床替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号